Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function
- Determine the effect of adjuvant aromatase inhibitor therapy on endothelial function in
postmenopausal women with breast cancer.
OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups
according to breast cancer hormone-receptor status (positive vs negative).
- Group 1 (hormone receptor-positive): Patients receive aromatase inhibition therapy for
up to 6 months in the absence of unacceptable toxicity.
- Group 2 (hormone receptor-negative): Patients do not receive adjuvant treatment.
Endothelial function is measured in both groups at baseline and at follow up by the room
temperature peripheral arterial tonometry (RT-PAT) index using the EndoPAT method.
Masking: Open Label, Primary Purpose: Treatment
Endothelial dysfunction as a result of aromatase inhibitor therapy
Nicole P. Sandhu, M.D., Ph.D.
United States: Federal Government
|Mayo Clinic||Rochester, Minnesota 55905|